• The prognosis in patients with coronary artery disease (CAD) is significantly worsened by
• Out of 545 subjects in PRACTICE registry, 267 (49.0%) subjects had normoglycemia and 64 (11.7%) had pre-diabetes at baseline. Baseline characteristics of this sub-group are presented in Table 1 .
RESULTS DISCUSSION
• The high rate of glycemic deterioration observed among patients with stable CAD in our study appears similar to that seen in concomitant diabetes or dysglycemia.
• The rate of glycemic deterioration among normoglycemic patients with stable CAD in contemporary practice is unclear.
• We obtained estimates of incident dysglycemia and predictors of transition to dysglycemia in the PRACTICE Registry a cohort of stable
SUMMARY AND CLINICAL IMPLICATIONS
• A high rate of glycemic deterioration was
• Incidence of glycemic deterioration was the primary outcome, defined as the composite of pre-diabetes or DM among normoglycemic subjects at baseline, as well as progression to DM among subjects with prediabetes at baseline.
• The incidence of glycemic deterioration was 55.6% over 5 years (169/304) subjects with evaluable data).
• On univariate analysis, significant predictors for glycemic deterioration included baseline BMI, WC, waist-hip ratio, FPG, triglyceride and LDL levels.
• On multivariate Cox-proportional odds models (stepwise adjusting for baseline demographics and our study appears similar to that seen in previous studies with populations having known DM risk factors of pre-diabetes or a positive family history of DM.
METHODS
• The PRACTICE Registry enrolled 545 subjects
the PRACTICE Registry, a cohort of stable CAD patients followed prospectively for 5 years.
g g y observed in this prospective secondary prevention cohort, despite annual reinforcement of optimal lifestyle behaviors and high use of evidence-based treatments.
• Baseline BMI, and levels of FPG and triglycerides were independently associated with glycemic deterioration
, BMI, FPG and triglyceride levels were independently associated with glycemic deterioration ( Table 2 ). • Proportion of subjects on evidence-based treatments: Aspirin 84%, ACEi or ARB 66%, Beta-blockers 64% and Statins 87%.
• Subjects were prospectively followed annually for 5 years at a single center in Brampton, Ontario, Canada.
• For this sub-study, we analyzed data from a • In the POP-ABC study 1 For this sub study, we analyzed data from a sub-cohort of PRACTICE registry who either had normoglycemia or pre-diabetes at baseline.
• Pre-diabetes was defined as fasting glucose (FPG) = 110-125 mg/dl or HbA1c = 6.0-6.4%.
• Diabetes (DM) was defined as any of:
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In the POP-ABC study , which prospectively observed offspring of parents with type 2 diabetes for a mean follow-up of 2.6 years, incidental prediabetes or diabetes developed at a rate of approximately 11% per year.
• In a meta-analysis of prospective studies 2 , the annual risk of progression to DM in people with Funding support for this analysis was provided by Astra Zeneca Canada.
